13
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Reconsidering hepatorenal syndrome

Throw in the towel? Not so fast!

, USAF, MC, , USAF, MC & , MD
Pages 15-24 | Published online: 30 Jun 2015

References

  • Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23(1): 164–76
  • Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34(6): 1242–51
  • Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105(1): 229–36
  • Rector WG Jr. Hepatorenal syndrome. In: Gitnick GL, ed. Principles and practice of gastroenterology and hepatology. 2nd ed. Norwalk, Conn: Appleton & Lange, 1994: 881–6
  • Arroyo V. New treatments for hepatorenal syndrome. (Editorial) Liver Transpl 2000; 6(3): 287–9
  • Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36(4 Pt 1): 941–8
  • Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. (Letter) J Hepatol 1999; 30(1): 174
  • Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38(1): 238–43
  • Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29(6): 1690–7
  • Chojkier M, Groszmann RJ, Atterbury CE, et al. A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. Gastroenterology 1979; 77(3): 540–6
  • Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27(1): 35–41
  • Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33(1): 43–8
  • Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicen- ter study. Gastroenterology 2002; 122(4): 923–30
  • Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36(2): 374–80
  • Guevara M, Gines P, Bandi JC, et al. Trans- jugular intrahepatic portosystemic shunt in hepatorenal syndrome: effect on renal function and vasoactive systems. Hepatology 1998; 28(2): 416–22
  • Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47(2): 288–95

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.